Opinions Paul MacDonald
Astrazeneca P L CAZNBUYSep 14, 2017
Paul MacDonaldStock price when the opinion was issued
As of Jun 08, 2026. Market Open.
You might be interested:
Very advanced pipeline will add significant revenue. Good story still intact.
Darren Sissons
Has broad platform of diseases they treat. Trades around 15x PE and pays a 2% dividend yield. Shares are still snapping back from some news in China last year, so there's more room to recover.
Jim LebenthalAbbvie and AZN are two good healthcare stocks, a sector in which you must be picky because of weakness. Both trade around 15x and pay around a 3% dividend yield.
Joe TerranovaIn oncology, but he isn't deeply familiar with its product pipeline. He can say, with quite a bit of confidence, that they've been improving on fundamentals since around 2017-18. ROC marched up from 6% to 13%, very consistent. Pretty good valuation at 13x EV/EBITDA. Well run.
He doesn't get too hung up on a weak couple of years. If the fundamentals are there, you just have to wait it out.
Likes the pipeline. A number of candidates to seek approval in the next couple of years, which will be a catalyst for earnings going forward. Fairly productive R&D engine. Also growth through tuck-in acquisitions. Relatively attractively priced given current growth outlook. Going to be second-fastest growing drug stock in Europe behind NVO. Yield is 3.06%.
(Analysts’ price target is $85.38)Darren SissonsBig breakthroughs in cancer. One drug failed recently. We're in the midst of a malaise of selling and going to cash. Great story.
Bruce Murray;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentOur PAST TOP PICK with AZN has triggered its stop at $71. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 1%, when combined with our previous guidance.
Premium contentThey rallied last summer, then faced headwinds last fall when a cancer drug failed to perform in trials and there was an investigation in their large Chinese business. Both problems are clearing now. They have a drug pipeline that should become a great growth story. Trades at 15x PE.
Jamie Murray Premium contentWe reiterate AZN as a TOP PICK. Recently reported earnings indicated a 19% increase in earnings and revenues. Management announced positive development on 9 new drugs worth $5 billion in future revenues and a plan to invest over $800 million in Ontario creating 700 jobs. The shares trade at 18x earnings and support a 30% ROE. We recommend trailing up the stop (from $52) to $64, looking to achieve $88 -- upside potential of 21%. Yield 1.4%
(Analysts’ price target is $88.24)
It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.